Evidence map›Paper›PMID 40387385›Full record

ArticleCancer medicine2025

FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors.

Kayla Bastian, Margarita Orozco-Moreno, Huw Thomas, Kirsty Hodgson, Eline A Visser, Emiel Rossing, Johan F A Pijnenborg, Nienke Eerden, Laura Wilson, Hasvini Saravannan and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Tumor cell intrinsic mechanisms of immune escape.Cell communication and signaling : CCS · 2026
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Kayla BastianNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
Margarita Orozco-MorenoNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
Huw ThomasNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'gorman Building, Newcastle University, Newcastle upon Tyne, UK.
Kirsty HodgsonNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
Eline A VisserSynthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, the Netherlands.
Emiel RossingSynthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, the Netherlands.
Johan F A PijnenborgGlycoTherapeutics B.V, Nijmegen, the Netherlands.
Nienke EerdenGlycoTherapeutics B.V, Nijmegen, the Netherlands.
Laura WilsonNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'gorman Building, Newcastle University, Newcastle upon Tyne, UK.
Hasvini SaravannanNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
Oliver HanleyNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
Grace GrimsleyDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina, USA.
Fiona FrameCancer Research Unit, Department of Biology, University of York, North Yorkshire, UK.
Ziqian PengNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
Bridget KnightNIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Paul McCullaghDepartment of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
John McGrathExeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Malcolm CrundwellInstitute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
Lorna HarriesInstitute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
Norman J MaitlandCancer Research Unit, Department of Biology, University of York, North Yorkshire, UK.
Rakesh HeerNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'gorman Building, Newcastle University, Newcastle upon Tyne, UK.
Ning WangThe Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, The University of Sheffield, Sheffield, UK.
Ethan D Goddard-BorgerThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Ramon Hurtado GuerreroUniversity of Zaragoza, Zaragoza, Spain.
Thomas J BoltjeSynthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, the Netherlands.
Richard R DrakeDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina, USA.
Emma ScottNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
David J ElliottNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
Jennifer MunkleyNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.ORCID https://orcid.org/0000-0002-8631-4531

Funding

Medical Research Council MC/PC/18057Prostate Cancer UK RIA16-ST2-011Prostate Cancer UK RIA21-ST2-006
6 · The paper itself

Abstract

backgroundAn unmet clinical need requires the discovery of new treatments for men facing advanced prostate cancer. Aberrant glycosylation is a universal feature of cancer cells and plays a key role in tumour growth, immune evasion and metastasis. Alterations in tumour glycosylation are closely associated with prostate cancer progression, making glycans promising therapeutic targets. Fucosyltransferase 8 (FUT8) drives core fucosylation by adding α1,6-fucose to the innermost GlcNAc residue on N-glycans. While FUT8 is recognised as a crucial factor in cancer progression, its role in prostate cancer remains poorly understood. METHODS &

resultsHere, we demonstrate using multiple independent clinical cohorts that FUT8 is upregulated in high grade and metastatic prostate tumours, and in the blood of prostate cancer patients with aggressive disease. Using novel tools, including PhosL lectin immunofluorescence and N-glycan MALDI mass spectrometry imaging (MALDI-MSI), we find FUT8 underpins the biosynthesis of malignant core fucosylated N-glycans in prostate cancer cells and using both in vitro and in vivo models, we find FUT8 promotes prostate tumour growth, cell motility and invasion. Mechanistically we show FUT8 regulates the expression of genes and signalling pathways linked to prostate cancer progression. Furthermore, we find that fucosylation inhibitors can inhibit the activity of FUT8 in prostate cancer to suppress the growth of prostate tumours.

conclusionsOur study cements FUT8-mediated core fucosylation as an important driver of prostate cancer progression and suggests targeting FUT8 activity for prostate cancer therapy as an exciting area to explore.

Indexed as

Enzyme InhibitorsFucosyltransferasesProstatic NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationFucoseGene Expression Regulation, NeoplasticGlycosylationHumansMaleMicePolysaccharidesXenograft Model Antitumor AssaysEnzyme InhibitorsFucoseFucosyltransferasesGlycoprotein 6-alpha-L-fucosyltransferasePolysaccharidescore fucosylationfucosylation inhibitorsfucosyltransferase 8 (FUT8)glycansprostate cancertherapeuticstumour growth

Identifiers

PMID40387385
PMCPMC12086987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.